Tom Robinson, vice president of global access at JDRF, lists 3 pieces of advice for groups looking to create indexes for other conditions similar to the Type 1 Diabetes (T1D) Index.
Other health groups are looking to develop indexes similar to the Type 1 Diabetes (T1D) Index, said Tom Robinson, vice president of global access at JDRF.
Transcript
Could indexes for other conditions be established, and what lessons from creating the T1D Index could be applied?
Well, I hope so. I've already had conversations with 3 other health groups who are looking at doing something similar. The concept of missing people, in particular, seems to have really resonated—like it's good epidemiology but it's also very personal, and often epidemiology fails to be personal. So, there's a lot of excitement around that.
There's kind of 3 pieces of advice that I'm giving people. The first is use modern data science. There is a world of difference between "I hacked this together on Excel" versus "this is coded up in a proper database....We could cross out all this sort of stuff. Use modern data science, it's worth it.
The second is definitely involve people with lived experience. People living with diabetes, their doctors and clinicians; involve scientists—that multidisciplinary approach made the index a lot better, and there are a lot of features of it that we wouldn't have without that involvement along the way.
And the third thing I should say is model the solutions as well as the problems. If you just describe the problem and admire the problem then people are going to say, "Well, so what? What do I do with this?" If you're going to go to all this effort, make sure you give them a clear, data-driven answer of where to look for what to do next.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More